ERBB2 and gastric cancer: Furthermore, approximately 5 to 69% of GC cases exhibit HER2 heterogeneity, which may cause underestimation of clinical response to HER2-based targeted therapies in those patients with heterogenous HER2 expression during clinical assessment (14).